TSXV:SVA

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Market Cap

CA$355.1m

Last Updated

2021/06/19 22:17 UTC

Data Sources

Company Financials +

Executive Summary

Sernova Corp., a clinical-stage regenerative medicine therapeutics company, focuses on the development and commercializing of its proprietary Cell Pouch System and associated technologies, including the cell pouch and systemic and/or locally immune protected therapeutic cells and tissues. More Details


Snowflake Analysis

Flawless balance sheet with moderate growth potential.

Share Price & News

How has Sernova's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: SVA is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: SVA's weekly volatility has decreased from 21% to 7% over the past year.


Market Performance


7 Day Return

-8.1%

SVA

1.3%

CA Biotechs

-2.1%

CA Market


1 Year Return

448.0%

SVA

-19.5%

CA Biotechs

33.6%

CA Market

Return vs Industry: SVA exceeded the Canadian Biotechs industry which returned -19.6% over the past year.

Return vs Market: SVA exceeded the Canadian Market which returned 34.7% over the past year.


Shareholder returns

SVAIndustryMarket
7 Day-8.1%1.3%-2.1%
30 Day1.5%3.8%1.0%
90 Day-12.2%-11.7%3.8%
1 Year448.0%448.0%-19.5%-19.5%38.0%33.6%
3 Year495.7%495.7%-1.7%-1.7%28.7%16.4%
5 Year426.9%426.9%33.0%33.0%59.6%35.6%

Long-Term Price Volatility Vs. Market

How volatile is Sernova's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Sernova undervalued compared to its fair value and its price relative to the market?

32.38x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate SVA's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate SVA's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: SVA is unprofitable, so we can't compare its PE Ratio to the North American Biotechs industry average.

PE vs Market: SVA is unprofitable, so we can't compare its PE Ratio to the Canadian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SVA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SVA is overvalued based on its PB Ratio (32.4x) compared to the CA Biotechs industry average (4.5x).


Future Growth

How is Sernova forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

79.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SVA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.5%).

Earnings vs Market: SVA is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: SVA's is expected to become profitable in the next 3 years.

Revenue vs Market: Insufficient data to determine if SVA's revenue is forecast to grow faster than the Canadian market.

High Growth Revenue: Insufficient data to determine if SVA's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if SVA's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Sernova performed over the past 5 years?

-18.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SVA is currently unprofitable.

Growing Profit Margin: SVA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: SVA is unprofitable, and losses have increased over the past 5 years at a rate of 18% per year.

Accelerating Growth: Unable to compare SVA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SVA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.7%).


Return on Equity

High ROE: SVA has a negative Return on Equity (-55.69%), as it is currently unprofitable.


Financial Health

How is Sernova's financial position?


Financial Position Analysis

Short Term Liabilities: SVA's short term assets (CA$9.6M) exceed its short term liabilities (CA$881.7K).

Long Term Liabilities: SVA has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: SVA is debt free.

Reducing Debt: SVA had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SVA has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: SVA has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of 16.8% each year.


Dividend

What is Sernova current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate SVA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SVA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SVA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SVA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SVA's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

10.5yrs

Average board tenure


CEO

Philip Toleikis

12.17yrs

Tenure

CA$367,500

Compensation

Dr. Philip M. Toleikis, B.A., M.Sc., Ph.D., has been the Chief Executive Officer and the President of Sernova Corp. since April 28, 2009. Dr. Toleikis is a seasoned and Experienced biotechnology executive,...


CEO Compensation Analysis

Compensation vs Market: Philip's total compensation ($USD294.59K) is below average for companies of similar size in the Canadian market ($USD444.91K).

Compensation vs Earnings: Philip's compensation has been consistent with company performance over the past year.


Board Members

Experienced Board: SVA's board of directors are seasoned and experienced ( 10.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 32.3%.


Top Shareholders

Company Information

Sernova Corp.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Sernova Corp.
  • Ticker: SVA
  • Exchange: TSXV
  • Founded: 1998
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$355.129m
  • Shares outstanding: 259.22m
  • Website: https://www.sernova.com

Location

  • Sernova Corp.
  • The Stiller Centre
  • 700 Collip Circle
  • London
  • Ontario
  • N6G 4X8
  • Canada

Listings


Biography

Sernova Corp., a clinical-stage regenerative medicine therapeutics company, focuses on the development and commercializing of its proprietary Cell Pouch System and associated technologies, including the ce...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/06/19 22:17
End of Day Share Price2021/06/18 00:00
Earnings2021/01/31
Annual Earnings2020/10/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.